以过氧化物酶体增殖物激活受体为靶点治疗2型糖尿病的药物研究进展  

Advance in drug development for type 2 diabetes mellitus targeted peroxisome proliferator-activated receptors

作　　者：李意奇 高健美 龚其海 Li Yiqi;Gao Jianmei;Gong Qihai(College of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 611137,China;Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education,Zunyi Medical University,Zunyi Guizhou 563099,China;School of Pharmacy,Zunyi Medical University,Zunyi Guizhou 563099,China)

机构地区：[1]成都中医药大学药学院,四川成都611137 [2]遵义医科大学基础药理教育部重点实验室暨特色民族药教育部国际合作联合实验室,贵州遵义563099 [3]遵义医科大学药学院,贵州遵义563099

出　　处：《遵义医科大学学报》2023年第2期214-220,共7页Journal of Zunyi Medical University

基　　金：国家自然科学基金资助项目(NO:82160756);遵义市科技计划项目(NO:遵市科合HZ字[2021]190)。

摘　　要：2型糖尿病是由于体内胰岛素分泌和(或)作用缺陷所引起的以糖代谢紊乱为特征的代谢性疾病,可引起多系统损害,为现代社会的常见病、多发病,严重危害人类健康。过氧化物酶体增殖物激活受体(PPARs)调控体内糖脂等多种代谢过程,是治疗2型糖尿病药物的重要分子靶标,一些新型PPARs激动剂已进入临床IV期研究,并有多个化合物处于临床前研发中,有望成为2型糖尿病的治疗药物。现对当前以PPARs为靶点治疗2型糖尿药物的研究进展进行综述。Type 2 diabetes mellitus(T2DM) is a metabolic disease caused by insufficient insulin secretion and(or) impaired functioning, and characterized by glycometabolism disorder, eventually causing multi-system damage.It is a common and frequently occurring disease in modern society and seriously endangers human health.Peroxisome proliferator-activated receptors(PPARs),which regulate a variety of glucolipid metabolic processes, are important targets in the treatment of type 2 diabetes mellitus.Some novel PPARs agonists have entered phase IV clinical studies, while several other compounds are currently in preclinical development for the treatment of type 2 diabetes mellitus.This article reviews the current research progress of drugs targeting PPARs in the treatment of type 2 diabetes mellitus.

关 键 词：2型糖尿病 PPARS 药物研究 

分 类 号：R587.7[医药卫生—内分泌]